Jazz Pharmaceuticals (JAZZ)
News
| May 29 | I exited $JAZZ for small profit. by Genyko |
| May 27 | Recommends $JAZZ via Markescope Stock Screener by MarkeScope |
| May 24 | $JAZZ back over $45 looking stronger by HighGrowthFinancial |
| May 24 | $JAZZ iz a screaming buy here cant reeiterated this enough. so cheap by johnkelly |
| May 24 | there goes $JAZZ by HighGrowthFinancial |
| May 24 | A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human ... |
| May 24 | current holding: short $AMZN, $AAPL; long $JAZZ, $RENN by dhakkan_d |
| May 23 | $JAZZ defending 200 still by HighGrowthFinancial |
| May 23 | Analysts Dish Out New Stock Ratings and Price Targets to the Public |
| May 23 | UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic... |
| May 23 | Credit Suisse Starts Jazz Pharmaceuticals (JAZZ) at Outperform Street Insider |
| May 22 | Coverage initiated on Jazz Pharma by Oppenheimer |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Jazz Pharmaceuticals Inc. is a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind its mission to improve patients’ lives. Headquartered in Dublin, Ireland with locations in California and Pennsylvania, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. Jazz Pharmaceuticals markets a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women’s health. The company was founded in 2003.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Jazz Pharmaceuticals is up 58.14% over the last year vs S&P 500 Total Return up 2.32%, Infinity Pharmaceuticals up 82.93%, and Cerus Corporation up 18.03%.
- JAZZ Total Returns
- ^SPXTR Total Returns
- INFI Total Returns
- CERS Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these JAZZ related companies
Pro Strategies Featuring JAZZ
Did Jazz Pharmaceuticals make it into our Pro Portfolio Strategies?
JAZZ Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other JAZZ Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| JAZZ | 44.61 | -1.46 | -3.17% | 2.591B |
| JAX | 8.60 | -0.05 | -0.58% | 51.81M |
| JASO | 0.9463 | -0.03 | -3.44% | 164.53M |
| JAKK | 18.23 | +0.09 | +0.50% | 472.00M |
| IVE | 59.84 | -0.97 | -1.60% | |
| IVD | 0.5801 | +0.00 | +0.00% | 19.95M |
| IVAN | 0.76 | -0.02 | -2.56% | 268.43M |
| IVAC | 7.80 | -0.08 | -1.02% | 183.29M |
| ITW | 55.92 | -1.28 | -2.24% | 27.54B |
| ITUB | 13.95 | -0.33 | -2.31% | 65.26B |
